AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 22 - (NewsRx.com) -- by Sonia Nichols, staff medical writer -- New research indicates vascular endothelial growth factor (VEGF) is an important marker for survival in patients with endometrial carcinoma.
The growth factor, which plays a key role in tumor-related angiogenesis, is a significant marker for different types of cancer, according to a report published in the February 2001 edition of Gynecologic Oncology. Researchers at National Taiwan University College of Medicine have established its relation to endometrial cancer progression and survival in females.
The research team, headed by Chi-An Chen, studied tumor samples acquired during surgery from 53 patients with endometrial cancers. These samples were assessed for cytosol VEGF, microvessel density, and other pathological features. VEGF often joins microvessel density (MVD) as an indicator of neovascularization within cancer tumors.
Patients with more advanced stages of endometrial cancer exhibited higher levels of VEGF and demonstrated greater MVD values also, according to Chen et al. These higher levels also correlated with findings of lymphovascular emboli and lymph node metastasis.
As values for VEGF increased, so did values for MVD. "Grade 3 tumor and overexpressed cytosol VEGF ([less than] 800 ...